CD274 and neoplasm: Recently, however, a PD-L1-negative TSDUT was shown to have a reduction in tumor burden following second-line treatment with tislelizumab in combination with etoposide and carboplatin, after failure of first-line treatment with four cycles of liposomal paclitaxel, cisplatin, and anlotinib [9].